Hantavirus vaccine in 2026?
As of Tue, 20 Oct 2026 11:32:05 UTC, Polymarket traders price Yes (3.0%). The market has $142K in volume and closes on Fri, 01 Jan 2027.
Updated:
Current odds
| Outcome | Chance | Yes price | No price |
|---|---|---|---|
| Yes | 3.0% | 3.0¢ | 97.0¢ |
Market details
- Venue: Polymarket
- Volume: $142K
- Liquidity: $56K
- Closes:
Resolution rules
This market will resolve to "Yes" if any vaccine intended for humans and inoculating against Hantavirus (including Hantavirus Pulmonary Syndrome (HPS) or Hemorrhagic Fever with Renal Syndrome (HFRS)) receives full approval from the U.S. Food and Drug Administration between market creation and December 31, 2026, 11:59 PM ET. Otherwise, this market will resolve to "No". The primary resolution source for this market will be official information from the FDA, including its list of approved vaccines (https://www.fda.gov/vaccines-blood-biologics/vaccines/vaccines-licensed-use-united-states), however a consensus of credible reporting may also be used.
Sources
Related markets
- Which countries will have an Ebola case in 2026?
- Measles cases in U.S. in 2026?
- How many large volcano eruptions (VEI ≥4) in 2026?
- Where will 2026 rank among the hottest years on record?
- 10.0 or above earthquake before 2027?
- How many 7.0 or above earthquakes in 2026?
DOXA is a liquidity aggregator for prediction markets that compares odds and depth across Polymarket, Kalshi and others and routes each trade for best execution with an AI assistant.